Quantcast
Last updated on April 18, 2014 at 1:21 EDT

BD Announces Results For 2013 Second Fiscal Quarter

May 2, 2013

FRANKLIN LAKES, N.J., May 2, 2013 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the second fiscal quarter ended March 31, 2013, representing an increase of 3.7 percent from the prior-year period, or 4.1 percent on a foreign currency-neutral basis.

“We continued to deliver solid performance in the second quarter. Our results for the first half of the year give us the confidence to raise guidance for fiscal year 2013,” said Vincent A. Forlenza, Chairman, CEO and President. “Additionally, our recent announcements of the BD Simplist(TM)( )product line and the Cato Software acquisition demonstrate how we are continuing to invest in innovation both organically and through strategic acquisition opportunities. We believe we are well positioned for continued success in fiscal year 2013 and beyond.”

Company Completes Acquisition of Cato Software Solutions

As previously announced on March 12, 2013, the Company completed its acquisition of Cato Software Solutions, or “CSS.” CSS, based in Vienna, Austria, provides a suite of comprehensive medication safety software solutions that are intended to prevent medication errors and improve efficiency in both pharmacy and drug delivery settings. CSS revenues will be reported in the BD Medical – Medical Surgical Systems unit.

Company Enters Pharmaceutical Manufacturing Market

On March 27, 2013, the Company announced its entrance into the pharmaceutical manufacturing industry with BD Simplist(TM),( )a line of ready-to-administer, prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and manufactured by BD Rx Inc., a wholly-owned subsidiary of BD, which plans to launch 20 to 30 drugs over the next few years. BD Rx Inc. revenues will be reported in the BD Medical – Medical Surgical Systems unit.

Second Quarter and Six-Month Fiscal 2013 Operating Results

Diluted earnings per share from continuing operations for the second quarter were $1.39, compared with $1.31 in the prior-year period, representing a 6.1 percent increase, or 7.6 percent on a foreign currency-neutral basis. Excluding the medical device tax that went into effect in January 2013 under the U.S. healthcare reform law, adjusted diluted earnings per share from continuing operations were $1.44, which represents growth of 9.9 percent. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the second quarter increased 11.5 percent.

For the six-month period ending March 31, 2013, diluted earnings per share from continuing operations were $2.74, compared with $2.45 in the prior-year period. This represents growth of 11.8 percent. Excluding the medical device tax, adjusted diluted earnings per share from continuing operations were $2.79. This represents growth of 13.9 percent excluding the medical device tax. Foreign currency had an immaterial impact on earnings per share for the six-month period.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.062 billion, representing an increase of 4.0 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. The segment’s revenue growth reflects solid sales in the Medical Surgical Systems and Diabetes Care units. As expected, we experienced lower revenue growth in the Pharmaceutical Systems unit, reflecting an unfavorable comparison to the prior-year period.

For the six-month period ended March 31, 2013, BD Medical revenues increased 3.7 percent, or 4.7 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $659 million, representing an increase of 4.6 percent compared with the prior-year period, or 4.9 percent on a foreign currency-neutral basis. The segment’s growth was driven by new product sales as well as international expansion in the Diagnostic Systems unit.

For the six-month period ended March 31, 2013, BD Diagnostics revenues increased 4.8 percent, or 5.5 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $279 million, representing an increase of 0.6 percent compared with the prior-year period, or 1.9 percent on a foreign currency-neutral basis. Segment revenue growth was driven by solid instrument placements in the U.S., as well as a favorable timing of orders in Advanced Bioprocessing. This was offset in part by softness in Western Europe due to austerity measures and timing of government funding in Japan.

For the six-month period ended March 31, 2013, BD Biosciences revenues increased 1.1 percent, or 2.6 percent on a currency-neutral basis.

Geographic Results

Second quarter revenues in the U.S. of $824 million represent an increase of 0.3 percent over the prior-year period. As expected, U.S. revenues were impacted by timing of orders. Revenues outside of the U.S. were $1.177 billion, representing an increase of 6.2 percent compared with the prior-year period, or 6.9 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products.

For the six-month period ended March 31, 2013, revenues in the U.S. were $1.654 billion, representing an increase of 1.6 percent compared with the prior-year period. Revenues outside of the U.S. were $2.247 billion, representing an increase of 5.3 percent when compared with the prior-year period, or 7.0 percent on a foreign currency-neutral basis.

Fiscal 2013 Outlook for Full Year

The Company is raising its previously communicated guidance for the full fiscal year 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to be between 4.5 and 5.0 percent, or an increase of 50 basis points. Reported revenue growth guidance remains consistent with the Company’s previously guided range of 3.5 to 4.0 percent. Reported diluted earnings per share from continuing operations for fiscal year 2013 are expected to be between $5.72 and $5.75, or an increase of $0.03 from the previous guidance range. This represents growth of 6.5 to 7.0 percent over 2012 adjusted diluted earnings per share of $5.37, which excludes the pension settlement charge in fiscal year 2012. On a currency-neutral basis, earnings per share are expected to increase 100 basis points to 8.5 to 9.0 percent. After adjusting for the impact of the medical device tax and foreign currency, adjusted diluted earnings per share are expected to grow 11.0 to 11.5 percent. In line with previously disclosed guidance, the Company plans to repurchase, subject to market conditions, about $500 million of its common stock in fiscal year 2013.

Conference Call Information

A conference call regarding BD’s second quarter results will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday, May 2, 2013. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international) through the close of business on Thursday, May 9, 2013, confirmation number 290460.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled “Fiscal 2013 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures, including “sequestration”, which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369


    BECTON DICKINSON AND COMPANY

    CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in thousands, except per share data)

                                                                                               Three Months Ended March 31,

                                                                                                                           2013        2012  % Change
                                                                                                                           ----        ----  --------

    REVENUES                                                                                                         $2,000,375  $1,928,961             3.7

    Cost of products sold                                                                                               982,256     941,184             4.4

    Selling and administrative                                                                                          514,610     487,694             5.5

    Research and development                                                                                            122,377     116,753             4.8
    ------------------------                                                                                            -------     -------             ---

    TOTAL OPERATING COSTS

         AND EXPENSES                                                                                                 1,619,243   1,545,631             4.8
         ------------                                                                                                 ---------   ---------             ---

    OPERATING INCOME                                                                                                    381,132     383,330            (0.6)

    Interest income                                                                                                      11,818      16,678           (29.1)

    Interest expense                                                                                                    (34,732)    (35,140)           (1.2)

    Other income, net                                                                                                     2,253       4,657           (51.6)
    -----------------                                                                                                     -----       -----           -----

    INCOME FROM CONTINUING OPERATIONS BEFORE

         INCOME TAXES                                                                                                   360,471     369,525            (2.5)

    Income tax provision                                                                                                 84,351      94,401           (10.6)
    --------------------                                                                                                 ------      ------           -----

    INCOME FROM CONTINUING OPERATIONS                                                                                   276,120     275,124             0.4

    (LOSS) INCOME FROM DISCONTINUED OPERATIONS

       NET OF INCOME TAX (BENEFIT) PROVISION OF

                                                             $(1,177) AND $7,544, RESPECTIVELY                             (483)     15,909              NM
                                                             ---------------------------------                             ----      ------             ---

    NET INCOME                                                                                                         $275,637    $291,033            (5.3)
    ----------                                                                                                         --------    --------            ----

    EARNINGS PER SHARE

    Basic:

    Income from continuing operations                                                                                     $1.42       $1.33             6.8

    (Loss) income from discontinued operations                                                   $                            -       $0.08              NM

    Net income                                                                                                            $1.42       $1.41             0.7

    Diluted:

    Income from continuing operations                                                                                     $1.39       $1.31             6.1

    (Loss) income from discontinued operations                                                   $                            -       $0.08              NM

    Net income                                                                                                            $1.39       $1.39               -

    AVERAGE SHARES OUTSTANDING

         Basic                                                                                                          194,609     206,426

         Diluted                                                                                                        198,143     209,803
         -------                                                                                                        -------     -------

    NM - Not Meaningful

    BECTON DICKINSON AND COMPANY

    CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in thousands, except per share data)

                                                                                                Six Months Ended March 31,

                                                                                                                           2013        2012  % Change
                                                                                                                           ----        ----  --------

    REVENUES                                                                                                         $3,900,567  $3,760,681             3.7

    Cost of products sold                                                                                             1,876,319   1,841,649             1.9

    Selling and administrative                                                                                        1,010,489     969,964             4.2

    Research and development                                                                                            240,538     228,981             5.0
    ------------------------                                                                                            -------     -------             ---

    TOTAL OPERATING COSTS

         AND EXPENSES                                                                                                 3,127,346   3,040,594             2.9
         ------------                                                                                                 ---------   ---------             ---

    OPERATING INCOME                                                                                                    773,221     720,087             7.4

    Interest income                                                                                                      19,740      32,126           (38.6)

    Interest expense                                                                                                    (69,761)    (64,518)            8.1

    Other income, net                                                                                                     2,967       4,272           (30.5)
    -----------------                                                                                                     -----       -----           -----

    INCOME FROM CONTINUING OPERATIONS BEFORE

         INCOME TAXES                                                                                                   726,167     691,967             4.9

    Income tax provision                                                                                                179,797     168,298             6.8
    --------------------                                                                                                -------     -------             ---

    INCOME FROM CONTINUING OPERATIONS                                                                                   546,370     523,669             4.3

    INCOME FROM DISCONTINUED OPERATIONS

       NET OF INCOME TAX PROVISION OF

                                                             $215,160 AND $14,871, RESPECTIVELY                         354,703      30,350              NM
                                                             ----------------------------------                         -------      ------             ---

    NET INCOME                                                                                                         $901,073    $554,019            62.6
    ----------                                                                                                         --------    --------            ----

    EARNINGS PER SHARE

    Basic:

    Income from continuing operations                                                                                     $2.79       $2.49            12.0

    Income from discontinued operations                                                                                   $1.81       $0.14              NM

    Net income (1)                                                                                                        $4.61       $2.63            75.3

    Diluted:

    Income from continuing operations                                                                                     $2.74       $2.45            11.8

    Income from discontinued operations                                                                                   $1.78       $0.14              NM

    Net income (1)                                                                                                        $4.53       $2.59            74.9

    AVERAGE SHARES OUTSTANDING

         Basic                                                                                                          195,528     210,385

         Diluted                                                                                                        199,068     213,970
         -------                                                                                                        -------     -------

    NM - Not Meaningful

    (1) Total per share amounts may not add due to rounding.

    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     REVENUE
     INFORMATION

    REVENUES
     BY
     SEGMENT
     AND
     GEOGRAPHIC
     AREA

     (Unaudited;
     Amounts
     in
     thousands)

                       Three Months Ended March 31,

                                                     2013       2012 % Change
                                                     ----       ---- --------

    BD
     MEDICAL
    --------

       United
        States                                   $412,485   $418,521          (1.4)

       International                              649,586    602,666           7.8
       -------------                              -------    -------

    TOTAL                                      $1,062,071 $1,021,187           4.0
    -----                                      ---------- ----------           ---

    BD
     DIAGNOSTICS
    ------------

       United
        States                                   $322,217   $318,597           1.1

       International                              336,723    311,422           8.1
       -------------                              -------    -------

    TOTAL                                        $658,940   $630,019           4.6
    -----                                        --------   --------           ---

    BD
     BIOSCIENCES
    ------------

       United
        States                                    $88,862    $83,986           5.8

       International                              190,502    193,769          (1.7)
       -------------                              -------    -------

    TOTAL                                        $279,364   $277,755           0.6
    -----                                        --------   --------           ---

    TOTAL
     REVENUES
    ---------

       United
        States                                   $823,564   $821,104           0.3

       International                            1,176,811  1,107,857           6.2
       -------------                            ---------  ---------

    TOTAL                                      $2,000,375 $1,928,961           3.7
    -----                                      ---------- ----------           ---

    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     REVENUE
     INFORMATION

    REVENUES
     BY
     SEGMENT
     AND
     GEOGRAPHIC
     AREA

     (Unaudited;
     Amounts
     in
     thousands)

                        Six Months Ended March 31,

                                                     2013       2012 % Change
                                                     ----       ---- --------

    BD
     MEDICAL
    --------

       United
        States                                   $837,851   $833,190           0.6

       International                            1,207,593  1,138,394           6.1
       -------------                            ---------  ---------

    TOTAL                                      $2,045,444 $1,971,584           3.7
    -----                                      ---------- ----------           ---

    BD
     DIAGNOSTICS
    ------------

       United
        States                                   $642,757   $630,220           2.0

       International                              668,108    620,542           7.7
       -------------                              -------    -------

    TOTAL                                      $1,310,865 $1,250,762           4.8
    -----                                      ---------- ----------           ---

    BD
     BIOSCIENCES
    ------------

       United
        States                                   $173,057   $163,913           5.6

       International                              371,201    374,422          (0.9)
       -------------                              -------    -------

    TOTAL                                        $544,258   $538,335           1.1
    -----                                        --------   --------           ---

    TOTAL
     REVENUES
    ---------

       United
        States                                 $1,653,665 $1,627,323           1.6

       International                            2,246,902  2,133,358           5.3
       -------------                            ---------  ---------

    TOTAL                                      $3,900,567 $3,760,681           3.7
    -----                                      ---------- ----------           ---

    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     REVENUE
     INFORMATION

    REVENUES
     BY
     BUSINESS
     SEGMENTS
     AND
     UNITS

    Three
     Months
     Ended
     March
     31,

     (Unaudited;
     Amounts
     in
     thousands)

                              United States
                              -------------

                                                     2013       2012 % Change
                                                     ----       ---- --------

    BD
     MEDICAL
    --------

       Medical
        Surgical
        Systems                                  $235,624   $237,599          (0.8)

       Diabetes
        Care                                      106,643    105,725           0.9

        Pharmaceutical
        Systems                                    70,218     75,197          (6.6)

    TOTAL                                        $412,485   $418,521          (1.4)
    -----                                        --------   --------          ----

    BD
     DIAGNOSTICS
    ------------

        Preanalytical
        Systems                                  $161,967   $163,455          (0.9)

        Diagnostic
        Systems                                   160,250    155,142           3.3
        ----------                                -------    -------

    TOTAL                                        $322,217   $318,597           1.1
    -----                                        --------   --------           ---

    BD
     BIOSCIENCES                                  $88,862    $83,986           5.8
    ------------                                  -------    -------           ---

    TOTAL
     UNITED
     STATES                                      $823,564   $821,104           0.3
    -------                                      --------   --------           ---


    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Three Months Ended March 31, (continued)

    (Unaudited; Amounts in thousands)

                                                             International
                                                             -------------

                                                                                   % Change
                                                                                  --------

                                             2013               2012               Reported       FXN      FX Impact
                                             ----               ----              --------        ---      ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                     $302,941             $281,340            7.7       8.4           (0.7)

       Diabetes Care                                 125,449              113,520           10.5      12.0           (1.5)

       Pharmaceutical Systems                        221,196              207,806            6.4       5.7            0.7
                                                                                                                      ---

    TOTAL                                           $649,586             $602,666            7.8       8.2           (0.4)
    -----                                           --------             --------            ---       ---           ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                        $168,064             $159,858            5.1       5.3           (0.2)

       Diagnostic Systems                            168,659              151,564           11.3      12.4           (1.1)
       ------------------

    TOTAL                                           $336,723             $311,422            8.1       8.8           (0.7)
    -----                                           --------             --------            ---       ---           ----

    BD BIOSCIENCES                                  $190,502             $193,769           (1.7)      0.2           (1.9)
    --------------                                  --------             --------           ----       ---           ----

    TOTAL INTERNATIONAL                           $1,176,811           $1,107,857            6.2       6.9           (0.7)
    -------------------                           ----------           ----------            ---       ---           ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Three Months Ended March 31, (continued)

    (Unaudited; Amounts in thousands)

                                                              Total
                                                              -----

                                                                                % Change
                                                                               --------

                                             2013            2012               Reported     FXN     FX Impact
                                             ----            ----              --------      ---     ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                     $538,565          $518,939           3.8     4.2           (0.4)

       Diabetes Care                                 232,092           219,245           5.9     6.6           (0.7)

       Pharmaceutical Systems                        291,414           283,003           3.0     2.4            0.6

    TOTAL                                         $1,062,071        $1,021,187           4.0     4.2           (0.2)
    -----                                         ----------        ----------           ---     ---           ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                        $330,031          $323,313           2.1     2.2           (0.1)

       Diagnostic Systems                            328,909           306,706           7.2     7.8           (0.6)
       ------------------

    TOTAL                                           $658,940          $630,019           4.6     4.9           (0.3)
    -----                                           --------          --------           ---     ---           ----

    BD BIOSCIENCES                                  $279,364          $277,755           0.6     1.9           (1.3)
    --------------                                  --------          --------           ---     ---           ----

    TOTAL REVENUES                                $2,000,375        $1,928,961           3.7     4.1           (0.4)
    --------------                                ----------        ----------           ---     ---           ----


    BECTON DICKINSON
     AND COMPANY

    SUPPLEMENTAL
     REVENUE
     INFORMATION

    REVENUES BY
     BUSINESS SEGMENTS
     AND UNITS

    Six Months Ended
     March 31,

    (Unaudited;
     Amounts in
     thousands)

                          United States
                          -------------

                                              2013       2012 % Change
                                              ----       ---- --------

    BD MEDICAL
    ----------

       Medical Surgical
        Systems                           $484,816   $486,015          (0.2)

       Diabetes Care                       219,047    211,251           3.7

       Pharmaceutical
        Systems                            133,988    135,924          (1.4)

    TOTAL                                 $837,851   $833,190           0.6
    -----                                 --------   --------           ---

    BD DIAGNOSTICS
    --------------

       Preanalytical
        Systems                           $328,916   $325,570           1.0

       Diagnostic Systems                  313,841    304,650           3.0
       ------------------                  -------    -------

    TOTAL                                 $642,757   $630,220           2.0
    -----                                 --------   --------           ---

    BD BIOSCIENCES                        $173,057   $163,913           5.6
    --------------                        --------   --------           ---

    TOTAL UNITED
     STATES                             $1,653,665 $1,627,323           1.6
    ------------                        ---------- ----------           ---

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Six Months Ended March 31, (continued)

    (Unaudited; Amounts in thousands)

                                                            International
                                                            -------------

                                                                                                          % Change
                                                                                                          --------

                                            2013               2012               Reported       FXN      FX Impact
                                            ----               ----              --------        ---      ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                    $589,687             $555,234            6.2       7.8           (1.6)

       Diabetes Care                                255,847              233,913            9.4      11.7           (2.3)

       Pharmaceutical Systems                       362,059              349,247            3.7       4.8           (1.1)

    TOTAL                                        $1,207,593           $1,138,394            6.1       7.7           (1.6)
    -----                                        ----------           ----------            ---       ---           ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                       $335,882             $314,365            6.8       8.1           (1.3)

       Diagnostic Systems                           332,226              306,177            8.5      10.1           (1.6)
       ------------------

    TOTAL                                          $668,108             $620,542            7.7       9.1           (1.4)
    -----                                          --------             --------            ---       ---           ----

    BD BIOSCIENCES                                 $371,201             $374,422           (0.9)      1.2           (2.1)
    --------------                                 --------             --------           ----       ---           ----

    TOTAL INTERNATIONAL                          $2,246,902           $2,133,358            5.3       7.0           (1.7)
    -------------------                          ----------           ----------            ---       ---           ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Six Months Ended March 31, (continued)

    (Unaudited; Amounts in thousands)

                                                             Total
                                                             -----

                                                                                                    % Change
                                                                                                    --------

                                            2013            2012               Reported     FXN     FX Impact
                                            ----            ----              --------      ---     ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                  $1,074,503        $1,041,249           3.2     4.0           (0.8)

       Diabetes Care                                474,894           445,164           6.7     7.9           (1.2)

       Pharmaceutical Systems                       496,047           485,171           2.2     3.1           (0.9)

    TOTAL                                        $2,045,444        $1,971,584           3.7     4.7           (1.0)
    -----                                        ----------        ----------           ---     ---           ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                       $664,798          $639,935           3.9     4.5           (0.6)

       Diagnostic Systems                           646,067           610,827           5.8     6.6           (0.8)
       ------------------

    TOTAL                                        $1,310,865        $1,250,762           4.8     5.5           (0.7)
    -----                                        ----------        ----------           ---     ---           ----

    BD BIOSCIENCES                                 $544,258          $538,335           1.1     2.6           (1.5)
    --------------                                 --------          --------           ---     ---           ----

    TOTAL REVENUES                               $3,900,567        $3,760,681           3.7     4.7           (1.0)
    --------------                               ----------        ----------           ---     ---           ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    SAFETY REVENUES

    (Unaudited; Amounts in thousands)

                                                    Three Months Ended March 31,
                                                 ----------------------------

                                                                                                 % Change
                                                                                                 --------

                                      2013                   2012              Reported      FXN       FX Impact
                                      ----                   ----             --------       ---       ---------

    TOTAL SAFETY REVENUES
    ---------------------

       United States                         $287,369               $282,733             1.6      1.6               -

       International                          227,066                205,369            10.6     11.1            (0.5)
       -------------                          -------                -------            ----                     ----

    TOTAL                                    $514,435               $488,102             5.4      5.6            (0.2)
    -----                                    --------               --------             ---      ---            ----

    BY SEGMENT
    ----------

       BD Medical                            $256,346               $235,928             8.7      9.0            (0.3)

       BD Diagnostics                         258,089                252,174             2.3      2.4            (0.1)
       --------------                         -------                -------             ---                     ----

    TOTAL                                    $514,435               $488,102             5.4      5.6            (0.2)
    -----                                    --------               --------             ---      ---            ----

                                                  Six Months Ended March 31,
                                                  --------------------------

                                                                                                 % Change
                                                                                                 --------

                                      2013                   2012              Reported      FXN       FX Impact
                                      ----                   ----             --------       ---       ---------

    TOTAL SAFETY REVENUES
    ---------------------

       United States                         $578,312               $573,345             0.9      0.9               -

       International                          447,299                402,326            11.2     12.7            (1.5)
       -------------                          -------                -------            ----                     ----

    TOTAL                                  $1,025,611               $975,671             5.1      5.7            (0.6)
    -----                                  ----------               --------             ---      ---            ----

    BY SEGMENT
    ----------

       BD Medical                            $508,202               $475,711             6.8      7.5            (0.7)

       BD Diagnostics                         517,409                499,960             3.5      4.1            (0.6)
       --------------                         -------                -------             ---                     ----

    TOTAL                                  $1,025,611               $975,671             5.1      5.7            (0.6)
    -----                                  ----------               --------             ---      ---            ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    Quarter-to-Date Fiscal 2013 Reconciliation - FX Impact

    (Unaudited; Amounts in millions, except per share data)

                                                                                       Three Months Ended March 31,
                                                                                      ----------------------------

                                                             Reported        Reported               Reported Growth       Foreign Currency           FXN          FXN

                                                              FY2013          FY2012                              $         Translation             Change       Growth
                                                              ------          ------                            ---         -----------            ------        ------

    REVENUES                                                          $2,000                $1,929                    $71                     $(8)           $79         4.1%

    Diluted Earnings per Share

    from Continuing Operations                                         $1.39                 $1.31                  $0.08                  $(0.02)         $0.10         7.6%

    FXN = Foreign Currency Neutral

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    Year-to-Date Fiscal 2013 Reconciliation - FX Impact

    (Unaudited; Amounts in millions, except per share data)

                                                                                       Six Months Ended March 31,
                                                                                       --------------------------

                                                             Reported        Reported               Reported Growth       Foreign Currency           FXN          FXN

                                                              FY2013          FY2012                              $         Translation             Change       Growth
                                                              ------          ------                            ---         -----------            ------        ------

    REVENUES                                                          $3,901                $3,761                   $140                    $(35)          $175         4.7%

    Diluted Earnings per Share

    from Continuing Operations                                         $2.74                 $2.45                  $0.29                   $0.00          $0.29        11.8%

    FXN = Foreign Currency Neutral

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY2013 Quarter-to-Date Reconciliation

    (Unaudited; Amounts in millions, except per share data)

                                                                                                               Three Months Ended March 31,
                                                                                                            ----------------------------

                                                                                        Reported       Medical Device                    Adjusted       Reported       Adjusted

                                                                                         FY 2013       Excise Tax(1)                      FY 2013        FY 2012        %Growth
                                                                                         -------        ------------                      -------        -------        -------

    Diluted Earnings per Share

    from Continuing Operations                                                                   $1.39                          $0.05             $1.44          $1.31            9.9%

    (1) Represents the medical device excise tax which went into effect in January 2013

        under the U.S. Patient Protection and Affordable Care Act.

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY2013 Year-to-Date Reconciliation

    (Unaudited; Amounts in millions, except per share data)

                                                                                                             Six Months Ended March 31,
                                                                                                             --------------------------

                                                                                        Reported       Medical Device                    Adjusted       Reported       Adjusted

                                                                                         FY 2013       Excise Tax(1)                      FY 2013        FY 2012        %Growth
                                                                                         -------        ------------                      -------        -------        -------

    Diluted Earnings per Share

    from Continuing Operations                                                                   $2.74                          $0.05             $2.79          $2.45          $13.9%

    (1) Represents the medical device excise tax which went into effect in January 2013

        under the U.S. Patient Protection and Affordable Care Act.

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    Quarter-to-Date Fiscal 2013 Reconciliation - Adjusted FX Impact

    (Unaudited; Amounts in millions, except per share data)

                                                                                              Three Months Ended March 31,
                                                                                          ----------------------------

                                                                    Adjusted       Reported                  Adjusted               Foreign            FXN          FXN
                                                                                                              Growth               Currency

                                                                     FY 2013        FY 2012                           $          Translation          Change       Growth
                                                                     -------        -------                         ---          -----------         ------        ------

    Diluted Earnings per Share

    from Continuing Operations                                               $1.44                  $1.31                  $0.13             $(0.02)         $0.15        11.5%

    FXN = Foreign Currency Neutral

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    Year-to-Date Fiscal 2013 Reconciliation - Adjusted FX Impact

    (Unaudited; Amounts in millions, except per share data)

                                                                                           Six Months Ended March 31,
                                                                                           --------------------------

                                                                    Adjusted       Reported                  Adjusted               Foreign            FXN          FXN
                                                                                                              Growth               Currency

                                                                     FY 2013        FY 2012                           $          Translation          Change       Growth
                                                                     -------        -------                         ---          -----------         ------        ------

    Diluted Earnings per Share

    from Continuing Operations                                               $2.79                  $2.45                  $0.34              $0.00          $0.34        13.9%

    FXN = Foreign Currency Neutral

    All figures rounded. Totals may not add due to rounding.

    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     INFORMATION

    FY2013
     Outlook
     Reconciliation

                        Reported

                         Basis              FX Impact         FXN Basis
                         -----              ---------         ---------

     Revenues
     -
     Full
     Year
     2013
     estimated
     growth                     3.5% - 4.0%           (1.0%)            4.5% - 5.0%

                       Full Year            Full Year

                                       2013             2012 % Increase
                                       ----             ---- ----------

                      (estimated)

     Reported
     Fully
     Diluted
     Earnings
     per
     Share

    from
     Continuing
     Operations     $           5.72 - 5.75            $5.30     NM

     Pension
     Settlement
     Charge
     (1)                                                0.06

     Adjusted
     Fully
     Diluted
     Earnings
     per
     Share

    from
     Continuing
     Operations     $           5.72 - 5.75            $5.37             6.5% - 7.0%
                                ===========            =====

    FX
     Impact                                                                    (2.0%)

     Adjusted
     FXN
     Growth                                                              8.5% - 9.0%

     Medical
     Device
     Excise
     Tax
     Impact
     (2)                                                                       (2.5%)

     Adjusted
     FXN
     Growth
     (excluding
     the
     medical
     device
     excise
     tax)                                                              11.0% - 11.5%
                                      Primarily represents a non-cash pension
                                      settlement charge associated with lump
                                      sum benefit payments made from the
                                      Company's U.S. supplemental pension
                                      plan, as such payments exceeded the
                                      service and interest components of the
    (1)                               plan's pension cost for the year.

                                      The charge also included settlement
                                      losses associated with certain foreign
                                      pension plans.

    (2)                               Represents the medical device excise tax
                                      which went into effect in January 2013
                                      under the U.S. Patient Protection and
                                      Affordable Care Act.

    NM - Not Meaningful

    FXN = Foreign Currency Neutral

    All figures rounded. Totals may
     not add due to rounding.

SOURCE BD (Becton, Dickinson and Company)


Source: PR Newswire